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It is hard to imagine a world in which infectious diseases like measles,polio, and others once ran rampant. This is due in large part to thedevelopment of vaccines and the implementation of vaccination
programs that have helped to curb the spread of disease. Before the
introduction of the measles vaccine in 1963, nearly everyone in the
United States got the disease and approximately 500 measles-associ-
ated deaths were reported each year. In contrast, with the widespread
use of the measles vaccine, we saw only 62 cases of measles last year,
or less than 1 case per million people.1 Before the inactivated polio
vaccine was developed in 1955, approximately 13,000 to 20,000
individuals became stricken each year with a virus that caused paralysis,
disability and, sometimes death. Widespread vaccination led to the
elimination of wild polio virus in the United States in 1979 and with
the efforts from the Pan American Health Organization, the virus was
eradicated from the western hemisphere in 1991.2
Immunization represents a very effective primary prevention
strategy to curb the rate of vaccine preventable diseases. Nowhere is
this more apparent than in the administration of the birth dose of
Hepatitis B to all newborns. In general, newborns do not have the
traditional risk of acquiring Hepatitis B infection, but they may when
they grow up. It is important to note that primary prevention strategies
reduce the incidence (i.e. new cases) of disease whereas secondary (e.g.
disease screening) and tertiary (e.g. aspirin after an MI to prevent
another MI) prevention strategies seek to reduce the prevalence (i.e.
number of existing cases) of a disease by allowing early treatment as
in the case of disease screening. Giving a pneumococcal vaccine to
someone with diabetes to reduce the risk of developing a severe
pneumonia is still a primary prevention strategy as the person does not
yet have pneumonia.
The Advisory Committee on Immunization Practices (ACIP) was
established to help determine the best use of vaccines in both the adult
and pediatric populations. The ACIP statements as published in
Morbidity and Mortality Weekly (MMWR) are the official CDC
endorsed recommendations for use of a particular vaccine. See Table
2 for a complete list of resources for vaccine information and materials.
The ACIP guidelines may differ from the vaccine’s package insert. If
there is a difference, standard of practice would suggest one follow the
ACIP guideline over the package insert. Until the MMWR publishes
the final recommendations of the ACIP, the recommendations are
considered provisional and will be noted as such in this article.
Pharmacists can play a leading role in vaccination by serving as an
advocate, facilitator, and active immunizer. As an advocate, pharma-
cists provide vaccine education while motivating people to get immu-
nized. As a facilitator, pharmacy’s can host other groups, such as the
visiting nurses association, to come into the pharmacy and vaccinate.
As an active immunizer, however, pharmacists serve their greatest role
by giving immunizations to adolescents and adults.
Immunization schedules for children, adolescents, and adults are
usually updated yearly and the most recent version should always be
referenced. See figures 1 and 2 for the current 2005-2006 immuni-
zation schedules. The adult schedule has been organized into two tables
to better illustrate vaccine indications. In an effort to make the adult
schedule resemble the pediatric schedule, age categories are used in the
first chart and indications in the second. Routine vaccines are high-
lighted in yellow and are above the broken line while vaccines for those
with specific risk factors are highlighted purple and/or are below the
broken line. Additionally, if an individual is known to have a specific
medical condition, then the vaccination by medical indication chart
can be used. For example, an
adult with diabetes should re-
ceive a yearly influenza shot, a
pneumococcal polysaccharide
shot, a tetanus booster every ten
years, as well as the MMR and
varicella vaccines if not previ-
ously received.
The childhood and adoles-
cent immunization schedule is
organized according to age and
vaccine type. Vaccines high-
lighted in yellow can be admin-
istered within the correspond-
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ing age range while green highlights indicate the catch up age range.
New to the schedule is the 11-12 year old pre-adolescent visit
highlighted in purple. At this visit, prior to entering middle school,
children should receive their first booster dose of tetanus, diphtheria,
and pertussis (Tdap) as well as the new meningococcal (Menactra®,
MCV4) vaccine. In the bottom right corner of the table are vaccines
enclosed by a broken red line. These vaccines, such as hepatitis A and
influenza, should be administered only in select populations. For
example, hepatitis A should be given to children 2 to 18 years of age
living in states and communities with higher rates of hepatitis A
infection and now universally for all children between 12 and 23
months of age. Yearly influenza shots should also be administered to
those children 24 months of age and older with certain chronic medical
conditions (see pediatric chart for more details).
The following section will discuss updates to specific vaccine
recommendations made for the 2005-2006 season.
Hepatitis A
Recommended by the ACIP in October 2005 and still considered
a provisional recommendation, all children between 12 and 23 months
of age should receive a two dose series of hepatitis A vaccine (Havrix®
or VAQTA®).3 This recommendation strengthens the previous one in
which the hepatitis A vaccine was only recommended for those
individuals 24 months to 18 years of age living in states and commu-
nities with higher rates of disease. These two doses should be admin-
istered at least 6 months apart.
Hepatitis B
The use of hepatitis B vaccine (Engerix-B® or Recombivax-HB®)
is also now recommended by the ACIP for all previously unvaccinated
adults that are seeking to become vaccinated regardless of risk factors
(i.e. sexual contact, IVDA, health care workers). This recommenda-
tion is still considered provisional by the CDC. 4 Additionally, the
hepatitis B vaccine should be administered to all newborns within 12
hours of birth as a primary prevention measure to protect against the
disease in the future.5 The use of standing orders for Hepatitis B vaccine
in the hospital is highly encouraged.
Tetanus, Diphtheria and Pertussis
Two new Tdap (tetanus, diphtheria, and acellular pertussis) vac-
cines have recently become FDA approved: Adacel® (Aventis-Pas-
teur) and Boostrix® (Glaxo Smith Kline). With the rising rates of
Table 1. Recent Changes in Vaccine Recommendations
Vaccine Indication(s) VIS Date Change
Hepatitis A •MSM1 01/09/2006 New recommendation: 
•IVDA    Children starting at 1 year of age
•Chronic liver disease
•Overseas travel to certain destinations 
Hepatitis B •CA kindergarten and 07/11/2001 •Universal infant vaccination
 7th grade entry req. •Emphasis on birth dose
•Birth to infant universal rec •Target adolescent immigrants from endemic countries
•Multiple sexual partners
•MSM
•IVDA
•Health care workers
•Hemodialysis patients 
Tdap •Adolescents: 11-18 09/22/2005 •Replaces next Td booster dose
(Tetanus, diphtheria,  booster dose2 •Preadolescent visit (11-12 yrs)
acellular pertussis) •Adults: 19-64 booster dose2
Meningococcal •11-12 year olds at preadolescent visit 10/07/2005 •Preadolescent visit at 11-12 years emphasized
•Prior to high school entry •Menactra® approved for 11-55 year olds
  (if not previously received)
•College freshman living in dorms
•Functional/anatomical asplenia
•Immunocompromised  
Varicella Children 12-18 months old 12/16/1998 New recommendations:2
•Focus on middle school, high school, and college
•All people >13 yrs without evidence of VZV as
 demonstrated by:
oDocumentation
oBorn before 1966
oHistory of VZV
oHistory of shingles
oPositive serology
Rabies High risk of exposure to rabies 01/12/2006 Removal of the intradermal rabies vaccine from market,
(i.e. veterinarians/animal handlers, etc) thus no need for the warning of an interaction
between antimalarials and rabies vaccine in the VIS.
Inactivated Influenza •6 mos-24 months universally recommended 10/20/2005 Individuals with muscle or nerve disorders which can
•> 24 mos, see Vaccine charts for indications compromise respiratory function 
1 MSM = Men who have sex with men (new CDC classification)
2 Provisional ACIP recommendations
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pertussis and waning immunity among adults, it was apparent there
needed to be adolescent and adult forms of pertussis containing
vaccine. Both Tdap formulations contain less diphtheria and pertussis
than the pediatric formulations (DTaP and DT), thus they cause less
local reactions while still eliciting an appropriate immune response.
Adacel® is indicated for individuals 11 to 64 years of age while Boostrix®
is indicated for 10-18 year olds. 6, 7 In June 2005, the ACIP approved
recommendations for the use of Tdap booster doses in place of Td in
adolescents 11-18 years of age. For individuals who have completed
the primary childhood series (DTP, DTaP), a Tdap booster dose is now
recommended in place of Td. The preferred age for Tdap vaccination
is 11-12 years old at the pre-adolescent visit. Similarly, for 11-18 years
olds who have received a booster dose of Td, a minimal interval of five
years is recommended before a dose of Tdap is administered to reduce
the risk of local and systemic side effects.8 For adults aged 19 to 64,
a Tdap booster dose (Adacel® only) in lieu of Td should be administered
if the last dose of Td was administered more than 10 years ago.
Additionally, those adults who have close contact with infants less than
12 months of age (i.e. parents, daycare workers, health care providers)
can receive a single dose of Adacel® even if the last Td dose was less than
10 years ago since infants are at the highest risk for pertussis-related
complications. 9 It should be noted that Tdap recommendations are
provisional at this time.
Meningococcal
A meningococcal tetravalent conjugate vaccine (Menactra®, MCV4)
was recently FDA approved for use in individuals aged 11 to 55 years
in January 2005. This vaccine contains the four main meningococcal
serogroups A, C, Y, and W-135 conjugated to 48 µg of diphtheria
toxoid. Compared to the polysaccharide vaccine, Menomune®
(MPSV4), the conjugated version, is expected by ACIP to have a
longer duration of immunity, have the ability to boost on repeated
doses, and eradicate nasal carriage of neisseria meningitidis as compared
to the polysaccharide version with a similar level of efficacy amongst
all serogroups.10 Despite the large amount of diphtheria toxoid used
in the conjugated vaccine, Menactra® is not indicated for immuniza-
tion against diphtheria.11 The ACIP recommends that MCV4 be
administered to 11 and 12 year olds along with a Tdap booster dose
during the suggested pre-adolescent visit where other appropriate
preventative services are provided. Including vaccine administration in
this visit will hopefully increase vaccination coverage rates and further
emphasize the importance of the pre-adolescent visit with their
primary care provider to patients and their families. For those that
remain unvaccinated past their pre-adolescent visit, MCV4 should be
administered prior to entering high school. Additionally, college
freshman living in dorms, individuals with functional or anatomical
asplenia, or those with immunosuppressive conditions should also
receive Menactra® or Menomune® if Menactra® is not available for
individuals aged 11-55.11 Recently, the CDC reported five cases of
Guillian-Barre Syndrome (GBS) in adolescents that received MCV4
in June, July, or November 2005.12 The CDC, however, is urging
continued vaccination since this adverse effect does not appear to be
occurring in higher than expected levels and no causal relationship has
been established. Individuals should be informed of the potential risk
prior to immunization with MCV4 and the current vaccine informa-
tion sheet reflects this potential adverse effect.
Varicella
In June 2005, the ACIP voted to expand and strengthen the use of
the varicella zoster (VZV) vaccine (Varivax®) among children, adoles-
cents and adults.13 Again, these recommendations are provisional until
the CDC publishes them in the MMWR. The current ACIP
recommendations state that
VZV vaccination require-
ments should be developed
within middle school, high
school, and college settings
and that these requirements
are regularly enforced by
school officials. New criteria
were also established to guide
people over 13 years of age on
the need for VZV vaccination
(see Table 1). To aid in in-
creasing vaccination rates, a
new vaccine, MMRV
(ProQuad®, Merck), was
FDA approved in September
2005 and combines the
Measles Mumps and Rubella
(MMR) vaccine with the
VZV vaccine. It can be used in
place of MMR and VZV vac-
cines separately for primary
immunization at ages 12 to
15 months and up to 12 years
Table 2: Immunization resources
Website Content
National Immunization Program • Selected vaccine product updates
www.cdc.gov/nip • Childhood, adolescent, and adult immunization schedules
• Vaccine information statements (http://www.cdc.gov/nip/publications/VIS/
default.htm)
• ACIP statements (http://www.cdc.gov/nip/ACIP/default.htm)
Centers for Disease Control and Prevention • MMWR publications
www.cdc.gov • Disease specific information 
Immunization Action Collation • Vaccine product information
www.immunize.org • Vaccine safety information 
• Email list serve (express@immunize.org) 
American Pharmacists Association • Immunization certificate programming
www.aphanet.org • Links to professional journals 
• Immunizing pharmacist list serve (apha-immpharm-subscribe@yahoogroups.com)
Vaccine Adverse Event Reporting System • Adverse event reporting system for vaccine administration 
www.vaers.hhs.gov
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of age as the 2nd dose of MMR when a 2nd dose of VZV is indicated
(e.g. during a VZV outbreak).14
Rabies
In 2004, the intradermal (ID) rabies vaccine, Imovax®, was recalled
from the market over concerns that certain lots of the vaccine were not
completely inactivated and could pose the potential for adverse events
in certain patient populations.15 Recently, the manufacturer of Imovax
ID voluntarily withdrew the vaccine from the market, which led to the
CDC revising the rabies vaccine information sheet in January 2006 (see
Table 1).
Influenza
Each year, 36,000 deaths are attributed to influenza and its
secondary complication, pneumococcal pneumonia. 16,17 Immuniza-
tion against these diseases remains a high priority to help prevent
morbidity and mortality in high risk groups. According to the National
Health Interview Survey16, 2003 influenza vaccination rates were low
for individuals with higher risk conditions (24% for 18-49 year olds,
46% for 50-64 year olds, and 66% for >65 year olds), falling well short
of the Healthy People 2010 goal of 90% coverage. For pneumococcal
vaccination, the 2010 goal is 90% coverage for those 65 years and older.
However, the Behavioral Risk Factor Surveillance System reported a
54% immunization rate for this group in whom, unlike influenza which
requires annual vaccination, most only need one shot in their lifetime.18
It is therefore exceedingly important that all capable health care
providers work to attain these goals.
There are three different strains of the influenza virus. Type A
influenza can cause moderate to severe illness, is responsible for
epidemics and pandemics, and can infect animals as well as humans.
Type B influenza typically infects younger children causing a less severe
illness than infection from type A. Type C influenza is rarely reported
to infect humans. Type A viruses are further classified by the presence
of hemagglutinin (H) and neuraminidase (N) surface proteins. Each
year, the trivalent inactivated (TIV) and the live attenuated intranasal
(LAIV) vaccines are formulated to contain two strains of influenza
antigen types A and one type B. The vaccine is reformulated every year
to account for changes in the virus. For the 2005-2006 year, the
influenza vaccine is composed of the A/California/7/2004 (H3N2)-
like, A/New Caledonia/20/99 (H1N1)-like, and B/Shanghai/361/
2002-like antigens.16
There are three different TIV influenza vaccines currently on the
market; FluZone® (Sanofi Pasteur), Fluvirin® (Chiron), and Fluarix
(GSK). The LAIV is marketed under the trade name of Flumist®
(MedImmune). The major difference between the TIV and LAIV
vaccines is that the TIV vaccine contains inactivated virus particles
whereas the LAIV vaccine contains live, attenuated viruses.
Indications for the TIV and LAIV vaccines differ and are therefore
not interchangeable. The TIV vaccine should be used, for example, in
individuals over 50 years of age, children 6-23 months old, residents
of long term care facilities, pregnant women, individuals six months
to 18 years old on chronic asprin therapy, those over six months with
a chronic illness such as diabetes, asthma, or cardiovascular disease, and
health care workers. In contrast, LAIV should only be used in healthy
individuals between the ages of 5 and 49 years. The current CDC
influenza recommendations have extended TIV vaccine use to indi-
viduals with any condition that can compromise respiratory function,
handling of respiratory secretions, or that can increase the risk of
aspiration (e.g. cognitive dysfunction, spinal cord injuries, seizure
disorders, or other neuromuscular disorders). Individuals with allergies
to eggs or other components of either vaccine should not be immu-
nized because of the potential of anaphylactic reactions.
The LAIV vaccine must be stored at -15 ºC (5ºF) or colder,
preferably in a frost-free freezer, and must be thawed before use.
Alternatively, the vaccine may be thawed in the refrigerator at 2-8 ºC
and used within twenty-four hours. This vaccine is temperature
sensitive and after nasal spray administration, replicates at 25 ºC (the
typical temperature of your nose and nasalpharynx). Replication is
inhibited at temperatures of 38-39 ºC (the typical temperature of your
lungs), preventing it from spreading into the lower respiratory tract and
causing influenza disease. Shedding of virus particles can occur for two
or more days after vaccination; however, transmission of the influenza
virus from person to person does not occur except in rare instances. The
most common side effects from the LAIV vaccine are rhinorrhea, nasal
congestion, headaches, fever, and sore throat. The most common side
effect with the TIV vaccine is mild soreness at the injection site. Fever,
malaise, and myalgia may also occur with the TIV vaccine six to twelve
hours after vaccination and may persist for one to two days.
Multidose vials of TIV contain thimerosal whereas single dose
syringes only contain trace amounts of thimerosal. Pediatric influenza
does not contain thimerosal. Concerns regarding thimerosal, a mer-
cury containing compound, causing autism have received much public
attention; however, no clear evidence to date has linked thimerosal
containing vaccines with autism. Despite this, efforts are underway to
further reduce the amount of thimerosal in these and other vaccines.
Immunization is strongly recommended for women who are or plan
to become pregnant during the influenza season since the TIV vaccine
can prevent one to two hospitalizations per 1000 pregnant women
immunized. 4 It should also be noted that neither the TIV nor LAIV
vaccines provides protection against avian (H5N1) influenza.
Pneumoccocal Disease
The current pneumococcal polysaccharide vaccine, PPV23,
(Pneumovax 23, Merck) was introduced in 1983 and is composed of
twenty-three different strains of pneumococcal polysaccharide coats
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of the bacteria. These strains are responsible for
approximately 88% of all pneumococcal disease.
Because polysaccharide vaccines are not reliably
immunogenic in children under two, PPV23 is
only administered to people over 2 years of age.
This vaccine can be administered either intra-
muscularly or subcutaneously to those 65 years
and older as well as in individuals over the age of
two with a chronic illness (e.g. cardiovascular
disease, pulmonary disease (excluding asthma)
diabetes, alcoholism, cirrhosis, etc). Those with an
immunosuppressive disorder such as asplenia (func-
tional or anatomical), HIV, Hodgkin’s disease, or
lymphoma should also receive the vaccine. The
vaccine’s efficacy is approximately 60-70% and
antibody levels wane over time. Therefore, one
revaccination dose is recommended at least five
years after the first, only for those individuals that
continue to be at high risk for pneumococcal
complications. Those over 65 should also receive
a second dose if their first dose was administered
five or more years ago and they were less than 65 at the time of the first
dose. 19
In conclusion, vaccination is one of the most important primary
prevention strategies to eliminating devastating diseases around the
world and at home. Pharmacists can play an essential role in promoting
and administering vaccines. For the pharmacist actively involved in
promoting and administering vaccines, there are numerous resources
available to help stay up-to-date. Table 2 contains a list of resources
for the most authoritative information on immunizations. Vaccine
recommendations can change frequently, so it is incumbent upon the
pharmacist to always provide the latest information to patients and
other providers.
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Figure 1. Child and Adolescent
Immunization Schedule
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Figure 2. Adult Immunization Schedule
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